Actimed Therapeutics Expands Intellectual Property Portfolio
06 févr. 2025 03h00 HE
|
Actimed Therapeutics
Two new composition of matter patents granted in the US and Europe Patents provide protection relating to lead compound S-pindolol benzoate (ACM-001.1), significantly strengthening company’s...
Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders
16 janv. 2025 03h00 HE
|
Actimed Therapeutics
Fabio Dorigotti brings over 25 years of clinical development experienceJoins Actimed following retirement of Frank Misselwitz London, UK – 16 January 2025. Actimed Therapeutics, a UK based clinical...
Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle
13 déc. 2024 03h00 HE
|
Actimed Therapeutics
London, UK – 13th December 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia...
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman
14 nov. 2024 03h00 HE
|
Actimed Therapeutics
Professor David Ebsworth to work closely alongside CEO Robin BhattacherjeeWill focus on fund raising efforts to support the planned IMPACT Phase 2b/3 trial for S-pindolol benzoate in cancer...
Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
04 sept. 2024 03h00 HE
|
Actimed Therapeutics
London, UK – 4th September 2024. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer
19 oct. 2023 03h00 HE
|
Actimed Therapeutics
London, UK – 19th October 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia
07 sept. 2023 03h00 HE
|
Actimed Therapeutics
First Investigational New Drug (IND) approval for Actimed - a significant corporate milestoneApproval granted for the IMPACT programme – IMProving cancer cachexia with ACTAs...
Actimed Therapeutics secures additional £4.75m funding in Series A extension round, almost doubling Series A proceeds
22 août 2023 04h00 HE
|
Actimed Therapeutics
London, UK – 22 August 2023 Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and...
Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia
26 juin 2023 03h00 HE
|
Actimed Therapeutics
London, UK – 26 June 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other...